# FONTANA (NCT05797168)

> Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05797168
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer; Lung Squamous Cell Carcinoma
- Interventions: Torvutatug samrotecan; Saruparib; Bevacizumab; Carboplatin; Palacaparib; Pembrolizumab
- Enrollment: 622
- Primary outcome: Number of participants with adverse events/serious adverse events
- Primary outcome: The number of participants with dose limiting toxicity(DLT), as defined in the protocol

## Commentary we found

- YouTube: 7
- Podcasts: 4
- X threads: 3
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=fontana-nct05797168

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05797168", "email": "<work email>"}; the inbox owner confirms by the emailed link.